SMARCA2 has become an appealing synthetic-lethal therapeutic target for various cancers, including non-small cell lung cancer (NSCLC), as mutational loss of SMARCA4 in many cancers leads to a functional dependency on residual SMARCA2 activity 22–25. Here, SMARCA2 is linked to non-small cell lung carcinoma.